Assessing Whether EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) Is Over- Or Undervalued

GLBE Stock
GLBE Stock

Bridgeway Capital Management, Inc.. has recently announced that it has increased stake in EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) by 40.26%. After grabbing 0.71 million shares, the institutional investor is now in possession of 0.2 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.57% having worth around $0.51 million. Moreover, Jane Street Capital LLC increased its share by 0.44 million to have a control over 0.44 million shares. And Squarepoint OPS LLC raised its holdings to 0.27 million shares by acquiring 0.37 million shares or 0.30% of the stake.

EyePoint Pharmaceuticals Inc. (EYPT) concluded trading on 08/27/20 at a closing price of $0.58, with 3.15 million shares of worth about $1.83 million changed hands on the day. Weekly performance of the stock remained positive as price took a surge of 0.94% during that period and on Thursday the price saw a gain of about 3.44%. Currently the company’s common shares owned by public are about 124.77M shares, out of which, 123.93M shares are available for trading.

A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 4 analysts are covering the EYPT stock and their offered price forecasts bring an average price target of $2.93. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $5.00 and could fall to a lowest price of $0.80. Analysts also issued an outlook of 2.20 for the EyePoint Pharmaceuticals Inc. stock for next 12 months. However, touching the estimated high of $5.00 would mean a gain of 88.4% for the stock.

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 20 times over the past 12 months. They bought 614,891 shares in 14 of the transactions. In 6 selling transactions, insiders dumped 46,408 shares.

FTIF SICAV – Biotechnology Discov, Vanguard Total Stock Market Index, and Franklin Biotechnology Discovery are the top 3 mutual funds which are holding stakes in EyePoint Pharmaceuticals Inc. FTIF SICAV – Biotechnology Discov is currently holding 2.39 million shares of worth totaling $1.69 million. The company recently came buying 0.0 shares which brought its stake up to 1.91% of the company’s outstanding shares. Franklin Biotechnology Discovery, after buying 1.75 million shares, have now control over 1.41% of the stake in the company. It holds 0.0 shares of worth $1.24 million.

EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) started trading at $0.6079, above $0.05 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $0.58, or with a gain of 3.44%. Stock saw a price change of 0.94% in past 5 days and over the past one month there was a price change of -20.13%. Year-to-date (YTD), EYPT shares are showing a performance of -62.55% which decreased to -59.69% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.51 but also hit the highest price of $2.69 during that period. While comparing its average daily trading volume of 2.35 million shares, we see that about 3.15 million changed hands on the day. The stock is currently trading -8.51% below its 20-day simple moving average (SMA20), while that difference is down -18.07% for SMA50 and it goes to -48.35% lower than SMA200.

Bridgeway Capital Management, Inc.. acquired 0.71 million shares of EyePoint Pharmaceuticals Inc. having value of about $0.51 million. Data submitted at the U.S SEC by Bridgeway Capital Management, Inc.. revealed that the firm now holds 0.2 million shares in the company valued at close to $118900.0, or have control over 40.26% stake in the company. EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) currently have 124.77M outstanding shares and institutions hold larger chunk of about 48.80% of that. Holding of mutual funds in the company is about 5.95% while other institutional holders and individual stake holders have control over 9.32% and 21.60% of the stake respectively.

The stock has a current market capitalization of $61.91M and its 3Y-monthly beta is at 1.25. It has posted earnings per share of -$0.46 in the same period. It has Quick Ratio of 3.80 while making debt-to-equity ratio of 12.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EYPT, volatility over the week remained 19.38% while standing at 11.21% over the month.

Analysts are in expectations that EyePoint Pharmaceuticals Inc. (EYPT) stock would likely to be making an EPS of -$0.07 in the current quarter, while forecast for next quarter ESPS is -$0.07 and it is -$0.22 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.1 which is -$0.02 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.15 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -3.60% while it is estimated to increase by 42.10% in next year.

Analysts at 4 brokerage firms have issued recommendations for the EyePoint Pharmaceuticals Inc. (EYPT)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.20. Out of those 4 Wall Street analysts, 2 recommended a “Buy” rating, while 2 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by B. Riley FBR on April 06, 2020 offering a Neutral rating for the stock and assigned a target price range of between $4 and $1 to it. Coverage by Laidlaw stated EyePoint Pharmaceuticals Inc. (EYPT) stock as a Buy in their note to investors on November 04, 2019, suggesting a price target of $5 for the stock.


Please enter your comment!
Please enter your name here